Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Mantle-Cell | 2 | 2019 | 9 | 1.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 245 | 1.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2022 | 11 | 0.830 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 29 | 0.810 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 37 | 0.810 |
Why?
|
| Quinazolinones | 2 | 2017 | 7 | 0.650 |
Why?
|
| Purines | 2 | 2017 | 39 | 0.640 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 375 | 0.610 |
Why?
|
| Remission Induction | 1 | 2018 | 111 | 0.610 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 86 | 0.600 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 659 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 468 | 0.490 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1070 | 0.440 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2023 | 6 | 0.430 |
Why?
|
| Disaster Medicine | 1 | 2010 | 10 | 0.350 |
Why?
|
| Mass Casualty Incidents | 1 | 2010 | 38 | 0.340 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 44 | 0.330 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 145 | 0.310 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2010 | 148 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 446 | 0.220 |
Why?
|
| Chromosomes, Human | 1 | 2021 | 14 | 0.200 |
Why?
|
| Clone Cells | 1 | 2021 | 67 | 0.200 |
Why?
|
| Microarray Analysis | 1 | 2021 | 63 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 47 | 0.190 |
Why?
|
| Dendritic Cells | 1 | 2022 | 201 | 0.180 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 5 | 0.170 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 10 | 0.170 |
Why?
|
| Karyotype | 1 | 2018 | 7 | 0.160 |
Why?
|
| Karyotyping | 1 | 2018 | 74 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 29 | 0.150 |
Why?
|
| Humans | 9 | 2023 | 68618 | 0.150 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2018 | 159 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 40 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1465 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2018 | 2007 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3259 | 0.100 |
Why?
|
| Manikins | 1 | 2010 | 42 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2021 | 7277 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 4848 | 0.080 |
Why?
|
| Aged | 2 | 2021 | 14862 | 0.070 |
Why?
|
| Curriculum | 1 | 2010 | 575 | 0.070 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.060 |
Why?
|
| Middle Aged | 2 | 2021 | 21147 | 0.060 |
Why?
|
| Adenine | 1 | 2022 | 46 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 349 | 0.050 |
Why?
|
| Piperidines | 1 | 2022 | 123 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2021 | 41 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 190 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2022 | 178 | 0.050 |
Why?
|
| Male | 2 | 2021 | 37321 | 0.040 |
Why?
|
| Female | 2 | 2021 | 38074 | 0.040 |
Why?
|
| Adult | 1 | 2018 | 21403 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1038 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1330 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 18 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 2358 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 7029 | 0.020 |
Why?
|